2025-04-23 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Review

**0) Summary Statistics:**

UNH, UnitedHealth Group Inc., is a diversified healthcare company.  The provided data shows mixed signals regarding UNH's performance relative to the S&P 500 (VOO). While UNH has shown substantial cumulative returns, it underperformed VOO in the period reviewed.  Recent price action indicates a downward trend, and earnings show some variability.


**1) Performance Comparison with S&P 500 (VOO):**

* **UNH Cumulative Return:** 42.48%
* **VOO Cumulative Return:** 76.31%
* **Return Difference:** -33.8% (UNH underperformed VOO by 33.8%).
* **Relative Underperformance:** 9.8% (This means UNH's underperformance is in the 9.8th percentile relative to its historical performance against the VOO,  based on a range of -43.3% to 53.4%.)

**Alpha and Beta Analysis:**

The provided Alpha and Beta data show mixed results. While the Alpha is generally positive, suggesting outperformance in some periods, it fluctuates significantly.  The Beta, a measure of volatility relative to the market, is consistently above 1, implying higher than market volatility.  The company's market capitalization increased substantially over the period.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 67.0% | 55.4% | 35.0% | 0.1 | 180.1 |
| 2016-2018  | 59.0% | 63.7% | 38.0% | 0.2 | 206.3 |
| 2017-2019  | 45.0% | 63.7% | 11.0% | 0.4 | 247.6 |
| 2018-2020  | -17.0% | 63.7% | -47.0% | 0.6 | 300.2 |
| 2019-2021  | 39.0% | 61.0% | -22.0% | 0.7 | 435.9 |
| 2020-2022  | 32.0% | 66.9% | 24.0% | 0.7 | 466.1 |
| 2021-2023  | 39.0% | 67.8% | 18.0% | 0.4 | 469.8 |
| 2022-2024  | -27.0% | 69.0% | -47.0% | 0.3 | 458.5 |
| 2023-2025  | -44.0% | 75.0% | -59.0% | 0.2 | 388.8 |


**2) Recent Price Movement:**

* **Closing Price:** $427.18
* **5-Day Moving Average:** $495.05
* **20-Day Moving Average:** $530.57
* **60-Day Moving Average:** $513.12

The price is significantly below all three moving averages, indicating a downtrend.


**3) Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.435 (Low to Medium Risk)
* **RSI:** 33.27 (Suggests the stock is oversold)
* **PPO:** -3.02 (Negative PPO suggests bearish momentum)
* **Recent Relative Divergence:** -44.3% (Significant recent relative underperformance against the market)
* **Expected Return (vs. S&P 500):** 114.6% over the long term (2+ years)  This is a significant potential for outperformance, but also needs to be viewed in context of higher volatility.  Note that this number was provided separately and requires further clarification of how this projection is derived.

The price change of $0.43 is relatively small and doesn't indicate a significant sudden movement (neither a sharp rise nor fall).


**4) Recent Earnings Analysis:**

| Date       | EPS    | Revenue         |
|------------|--------|-----------------|
| 2024-11-04 | 6.56   | $100.82 B       |
| 2024-08-09 | 4.58   | $98.86 B       |
| 2024-05-09 | -1.53  | $99.80 B       |
| 2023-11-06 | 6.31   | $92.36 B       |
| 2024-11-04 | 6.31   | $92.36 B       | *(Duplicate entry)*


Earnings show significant variability, with a notable loss in Q2 2024. Revenue remains relatively stable and high.  The duplicate entry needs clarification.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $100.81B   | 21.14%        |
| 2024-09-30 | $100.82B   | 22.84%        |
| 2024-06-30 | $98.86B    | 22.31%        |
| 2024-03-31 | $99.80B    | 23.05%        |
| 2023-12-31 | $94.43B    | 23.30%        |

Revenue is generally high and stable. Profit margins are healthy but show some fluctuation.

**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|-------------|---------------|
| 2024-12-31 | $92.66B    | 5.98%         |
| 2024-09-30 | $94.53B    | 6.41%         |
| 2024-06-30 | $89.36B    | 4.72%         |
| 2024-03-31 | $86.69B    | -1.63%        |
| 2023-12-31 | $88.76B    | 6.15%         |

Equity fluctuates, and ROE shows a significant negative value in Q1 2024, likely linked to the EPS loss in that quarter.


**6) Overall Analysis:**

UNH shows strong revenue and generally healthy profit margins, but recent performance has lagged the S&P 500.  Technical indicators suggest the stock is currently oversold, and the projected long-term return relative to the S&P 500 is significant, but only if this projection is validated.  The high beta indicates substantial volatility.  Further investigation is needed to reconcile the apparently conflicting signals from the different analyses (strong financials but underperformance and negative technical indicators), especially the significant negative value in Q1 2024 ROE and the significant variability in EPS.  The duplicate data entry needs clarification.  A more detailed analysis including an examination of the company's competitive landscape and future growth prospects is recommended before making any investment decisions.
